Search Results

Pages

HIV Antibodies 

https://www.iavi.org/our-work/hiv-antibodies/

Pages

IAVI Vaccine Design & Development Laboratory

https://www.iavi.org/united-states/iavi-vaccine-design-development-laboratory/

Pages

Global Access

https://www.iavi.org/our-work/global-access/

Pages

Epidemiology

https://www.iavi.org/our-work/epidemiology/

Pages

Emerging Infectious Diseases

https://www.iavi.org/our-work/emerging-infectious-diseases/

Pages

IAVI Africa

https://www.iavi.org/africa/iavi-africa/

Pages

Africa Clinical Research Centers

https://www.iavi.org/africa/africa-clinical-research-centers/

People

W. Ripley Ballou

November 8, 2023

W. Ripley (“Rip”) Ballou, M.D., is chief medical officer. He provides guidance across a range of IAVI programs.

Ballou previously was Vice President and Head at GSK Global Vaccines U.S. R&D Center in Rockville, Maryland. Prior to that, he was Vice President and Head, Clinical Research and Translational Science, Vaccine Discovery and Development at GSK Vaccines. He also served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health, at the Bill & Melinda Gates Foundation. Trained in internal Medicine and infectious diseases, he began his work on vaccines at the Walter Reed Army Institute of Research where he led the team that with GSK co-developed RTS,S, the world’s most advanced malaria vaccine.

Ballou received his M.D. from Emory University School of Medicine and completed his residency and fellowship in infectious diseases at Walter Reed Army Medical Center.

https://www.iavi.org/person/w-ripley-ballou/

Pages

Funders

https://www.iavi.org/about-iavi/funders/

Pages

Tuberculosis

https://www.iavi.org/our-work/tuberculosis/